Lab Information

Jesse Papenburg (MD)

Scientist
Centre for Outcomes Research and Evaluation
Department of Pediatrics (McGill)

Research Profile

 Fundamental: 10%
 Clinical: 20%
 Epidemiology: 60%
 Evaluation: 10%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Influenza • respiratory syncytial virus (RSV) • children • epidemiology • diagnosis • COVID-19

Research Interests

My research focuses on the epidemiology, diagnosis, treatment, and prevention of severe viral lower respiratory tract infections in children. I actively engage in knowledge translation in my field by contributing to national and provincial guidelines on RSV immunoprophylaxis, influenza antiviral treatment, and SARS-CoV-2 diagnostics and treatment. I am also a voting member of Canada's National Advisory Committee on Immunization (NACI) and chair of NACI’s influenza working group.


Team Members

Name Position

Latest Publications

  1. Raad, C., Ouldali, N., Lebel, M., Paquette, M., Gilca, R., Papenburg, J., Lewin, A. & Renaud, C. (2024). Use of the moving epidemic method to guide the launch of palivizumab immunization campaigns for respiratory syncytial virus in Québec, Canada. Canadian journal of public health = Revue canadienne de sante publique.
  2. Marom, A., Papenburg, J. & Burstein, B. (2024). The Critical Lens: It is time to start using the right test for febrile young infants. Paediatrics & child health, vol. 29, p. 419-421.
  3. Gil, A., Siu, W., Papenburg, J., Gil, A., Siu, W. & Papenburg, J. (2024). Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2024-2025. Canada communicable disease report = Releve des maladies transmissibles au Canada, vol. 50, p. 381-386.
  4. Doyon-Plourde, P., Sinilaite, A. & Papenburg, J. (2024). Summary of the National Advisory Committee on Immunization (NACI) Supplemental Guidance on Influenza Vaccination in Adults 65 Years of Age and Older. Canada communicable disease report = Releve des maladies transmissibles au Canada, vol. 50, p. 387-392.
  5. Reszetnik, G., Hammond, K., Mahshid, S., AbdElFatah, T., Nguyen, D., Corsini, R., Caya, C., Papenburg, J., Cheng, M. P. & Yansouni, C. P. (2024). Next-generation rapid phenotypic antimicrobial susceptibility testing. Nature communications, vol. 15, p. 9719.
  6. Charland, K., Quach, C., Papenburg, J., Pierce, L., Tuong Nguyen, C., Saucier, A., Barbosa Da Torre, M., Hamelin, M.-È., Carbonneau, J., Boivin, G. & Zinszer, K. (2024). Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada. Vaccine, vol. 43, p. 126489.
  7. Charland, K., Pierce, L., Saucier, A., Hamelin, M.-È., Barbosa Da Torre, M., Carbonneau, J., Nguyen, C. T., De Serres, G., Papenburg, J., Boivin, G., Quach, C. & Zinszer, K. (2024). Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study. Epidemiology and infection, vol. 152, p. e103.
  8. Assad, Z., Papenburg, J. & Ouldali, N. (2024). Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis. The Lancet. Child & adolescent health, vol. 8, p. 708-709.
  9. Charland, K., Pannunzio, M., Greenspan-Ardman, E., Saucier, A., Pierce, L., Hamelin, M.-E., Barbosa Da Torre, M., Carbonneau, J., Tuong Nguyen, C., De Serres, G., Papenburg, J., Boivin, G., Quach, C. & Zinszer, K. (2024). SARS-CoV-2 seroprevalence and mental health of school staff: a cross-sectional study of schools from four areas of Montreal, Quebec in 2021. BMJ open, vol. 14, p. e081838.
  10. Campbell, A. J., Anpalagan, K., Best, E. J., Britton, P. N., Gwee, A., Hatcher, J., Manley, B. J., Marsh, J., Webb, R. H., Davis, J. S., Mahar, R. K., McGlothlin, A., McMullan, B., Meyer, M., Mora, J., Murthy, S., Nourse, C., Papenburg, J., Schwartz, K. L., Scheuerman, O., Snelling, T., Strunk, T., Stark, M., Voss, L., Tong, S. Y. C., Bowen, A. C. & Staphylococcus aureus Network Adaptive Platform Paediatric and Youth (SNAP-PY) working groupSNAP Global Trial Steering Committee (2024). Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials. JAMA pediatrics, vol. 178, p. 1066-1071.
More on PubMed 



See also

Card image
Matthew
Cheng


See profile
Card image
Cédric
Yansouni


See profile
Card image
Marie-Astrid
Lefebvre


See profile
Card image
Nandini
Dendukuri


See profile
Card image
Makeda
Semret


See profile
Card image
Michael
Libman


See profile